Lila Hope is a partner in Cooley’s global life sciences partnering and licensing group. She focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. She counsels clients ranging from privately-held companies to Fortune 500 companies. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and cross-border licenses. In addition, she counsels clients' management, operational and legal teams on matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions. 
Some representative transactions Lila closed in 2018 include two immunotherapy platform collaborations (FATE/ONO and Xyphos/PICI), five cross-border transactions (I-Mab/Morphosys, Rigel/Kissei, Zai/TESARO, Ascendis/VISEN and Ark/Roche), and a platform collaboration between Takeda Pharmaceuticals and Denali.